Caribou Biosciences (CRBU) Total Current Liabilities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Total Current Liabilities data on file, last reported at $19.7 million in Q1 2026.

• Quarterly Total Current Liabilities fell 30.95% year-over-year to $19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 million (down 30.95% YoY) and the FY2025 annual result came in at $25.4 million, down 17.09% from the prior year.
• Total Current Liabilities eased to $19.7 million in Q1 2026 per CRBU's latest filing, from $25.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $34.4 million in Q2 2023 and bottomed at $19.7 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $28.5 million (2025), against an average of $28.2 million.
• The widest annual swing landed in 2024, when Total Current Liabilities soared 30.88%; it then slumped 30.95% in 2026.
• Tracing CRBU's Total Current Liabilities over 5 years: stood at $28.1 million in 2022, then advanced by 0.62% to $28.3 million in 2023, then climbed by 8.3% to $30.7 million in 2024, then declined by 17.09% to $25.4 million in 2025, then fell by 22.59% to $19.7 million in 2026.
• Per Business Quant, the three latest CRBU Total Current Liabilities figures stand at $19.7 million (Q1 2026), $25.4 million (Q4 2025), and $28.1 million (Q3 2025).

Peer Comparison